Clinical Trials Search
Clinical Trial 18406
Cancer Type: Malignant Hematology
Interventions:AZD1775; Belinostat; MK-1775 (AZD1775); PXD101 (Belinostat)
Study Type: Treatment
Phase of Study: Phase I
- Jeffrey Lancet
A Phase 1 Study of AZD1775 in Combination with Belinostat in Relapsed and Refractory Myeloid Malignancies and Selected Untreated Patients with Acute Myeloid Leukemia
The purpose of this study is to test the safety of giving belinostat with AZD1775.
To identify the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) for a regimen combining AZD1775 with belinostat in patients with refractory/relapsed acute myeloid leukemia (AML), chronic myeloid leukemia in blast crisis (CML-BC), or intermediate-2 or high-risk myelodysplastic syndrome (MDS), and selected previously untreated poor-prognosis patients with AML.